ArticleInternational journal of hematology2026
Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".
Hirotaka Matsui et al.PubMed ↗Publisher ↗
No numbers read from the abstract.